To address the threat of AMR, the central government is preparing to change the regulations for antimicrobial drugs. Under the new proposal, approval from a central authority will be required before drug manufacturing can begin.
new drug rules
The central government has taken a significant step to address antimicrobial resistance (AMR), the growing resistance of bacteria and other microorganisms to drugs. The Union Ministry of Health and Family Welfare has proposed amendments to the New Drugs and Clinical Trials Rules, 2019. Under this amendment, antimicrobial drugs will be included in the definition of "new drug." This will enhance central oversight of the manufacturing and quality of these drugs.
Ministry issued notification
The Ministry of Health issued a draft gazette notification, GSR 983 (E), on November 6th in this regard. It proposes amendments to Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019. According to information released by the ministry, antimicrobial resistance has become a major health challenge facing the world today. In this condition, drugs become less effective against bacteria and other microorganisms, making infection treatment difficult.
India is also making continuous efforts to address this challenge. The G20 New Delhi Leaders' Declaration also emphasized the need for a "One Health" approach to combat AMR. It recognizes the interconnected health of humans, animals, and the environment, and calls for coordinated action.
Preparations to curb the manufacturing of medicines without adequate testing
According to the Ministry, concerns have been raised about the granting of manufacturing licenses to some antimicrobial drug products without adequate regulatory scrutiny. In many cases, essential tests, such as bioavailability, bioequivalence, and stability studies, are required to ensure the quality, safety, and efficacy of drugs. The lack of these tests can raise questions about the quality and efficacy of drugs. Prescribing poor-quality or less effective antimicrobial drugs to patients can compromise the treatment of infections. Furthermore, the use of such drugs can contribute to the increased risk of AMR.
Central authority's approval is required before construction license
The proposed amendment, when implemented, will bring antimicrobial drugs under the regulatory framework for new drugs. Under this, drug manufacturers will have to obtain permission from the Central Licensing Authority (CLA) before applying for a manufacturing license from the respective State Licensing Authority (SLA).
The government believes that this system will enable better central oversight of the drug manufacturing process and help ensure the quality, safety, and efficacy of antimicrobial drugs. Currently, the Ministry has invited objections and suggestions from the public and relevant stakeholders on this proposed amendment. After considering these suggestions, the central government will decide on finalizing the amendment.






